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S U M M A R Y
Objectives: Despite the widespread use of probiotics, there are limited data regarding their safety. The
aims of this study were to characterize inpatient probiotic use and to determine the incidence of
probiotic-related bloodstream infections due to Lactobacillus acidophilus/Lactobacillus bulgaricus.
Methods: This study was a two-part retrospective study conducted at a large academic medical center.
The ﬁrst part was the characterization of probiotic use during 2007–2008, which included the type of
prescribing provider, choice of probiotic prescribed, indications for use, and presence of potential risk
factors for probiotic infection among recipients; the second part was the determination of the incidence
of probiotic-related bloodstream infections due to L. acidophilus/L. bulgaricus for September 2000–
August 2008.
Results: Probiotic use was uncommon (0.4%). Ninety-six percent of patients received Lactobacillus-
based compounds. Use was common in patients at theoretical risk for probiotic infection. The maximum
estimated incidence of probiotic-related bacteremia due to L. acidophilus/L. bulgaricus during the 8-year
period was 0.2%.
Conclusions: L. acidophilus/L. bulgaricus probiotic use at our institution appeared to be associated with a
minimal risk of probiotic-related infection, even though it was used at a high frequency among
inpatients who could be considered at high theoretical risk for probiotic-related bloodstream infection.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Probiotics have been deﬁned as ‘‘. . .live microorganisms, which
when administered in adequate amounts confer a health beneﬁt on
the host’’.1 A theoretical concern for probiotic-related infection
exists, given that the organisms present in the probiotic supple-
ments are viable. Probiotics have been reported to have
therapeutic applications for many medical conditions,2 but have
been regulated as food supplements by the United States Food and
Drug Administration (FDA).3,4 As such, although they have been
widely commercialized as food products, they have never been
subjected to the comprehensive FDA safety evaluations that
pharmaceuticals receive. Subsequently, probiotic safety data are
scarce. An extensive review of the literature performed by the
Agency for Healthcare Research and Quality (AHRQ), found that
adverse events due to probiotics were poorly documented and that
monitoring for probiotic-related infections was not routinely
done.5 The acquisition of probiotic safety data is further
complicated by the fact that a variety of yeast and bacterial
species and strains, which may vary in risk, have been used in
probiotic preparations,6 and because manufacturing standards* Corresponding author.
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species of probiotic agent.7 Furthermore, until the FDA established
a requirement for reporting of probiotic adverse events to a central
registry in 2006, there was no surveillance program for probiotic-
associated infections.8
The AHRQ review previously referenced also noted that there
was some indication that patient health status was associated with
the risk of a probiotic-related adverse event, and noted that case
studies reporting adverse events were described among health
compromised rather than healthy individuals, and most often
consisted of a serious probiotic-related infection. However, a
subgroup analysis of existing randomized clinical trials did not
demonstrate a statistically signiﬁcant increased risk of probiotic
adverse events among critically ill patients using probiotics
relative to control patients with similar patient characteristics.5
Another review that included data from 7526 patients enrolled in
143 clinical trials who were receiving 11 different Lactobacillus
species, ﬁve different Biﬁdobacterium species, and two streptococcal
species as probiotics, identiﬁed no probiotic-related infections.9 No
increase in the incidence of Lactobacillus bacteremia was found in
either Finland or Sweden after widespread use of Lactobacillus
probiotics in dairy products.10,11 However, there have been sporadic
case reports of probiotic-related infections with both Saccharomyces
boulardii and Lactobacillus species-based probiotic preparations.12–
18Most have occurred in immunocompromised patients.12,13,17Datases. Published by Elsevier Ltd. All rights reserved.
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limited to small studies investigating patients with severe
neutropenia,19 liver transplant recipients,20 and HIV-infected
patients21,22 receiving Lactobacillus reuteri, Enterococcus faecium,
or Lactobacillus rhamnosus-based probiotics, all of which reported no
probiotic-associated infections. The presence of abnormal heart
valves and impaired intestinal integrity have also been proposed as
risk factors for probiotic-related infection.13,23 Lactobacillus is a
known possible cause of endocarditis, especially in the presence of
abnormal heart valves,16,24 and a case report describes Lactobacillus
probiotic-associated endocarditis in a patient with underlying
mitral regurgitation.18To our knowledge, there have been no studies
to date that have investigated probiotic safety in patients with
underlying abnormal heart valves. Studies looking speciﬁcally for
probiotic-related infections among patients with impaired intesti-
nal integrity are limited to a single study investigating patients with
inﬂammatory bowel disease,25 and even though there were no
probiotic-related infections, it is known that impairment of the
intestinal mucosal barrier may favor bacterial translocation.26
The aim of this study was to characterize inpatient prescription
probiotic use at an academic medical center, with a particular focus
on evaluating the use of probiotics in patients considered at
theoretical high risk for probiotic-related infection. We also sought
to quantify the incidence of these infections.
2. Methods
2.1. General
This study was a two-part retrospective study that was
performed at the Moses and Weiler hospitals of Monteﬁore
Medical Center, a large tertiary care medical center located in the
Bronx, New York that serves as the University Hospital for the
Albert Einstein College of Medicine. Both hospitals combined had
1145 beds and shared the same microbiology laboratory and
electronic medical record system. All probiotics had non-formu-
lary status during the period encompassed by this investigation
(2000–2008), and could be ordered electronically via physician
order entry from a non-formulary compendium, or by directly
typing in the desired product. All probiotic orders required
telephone contact with the pharmacy prior to dispensing, but
no request was denied. This study was approved by the Monteﬁore
Medical Center Institutional Review Board.
The statistical analysis was performed using Stata 10. Chi-square
and Fisher’s exact tests were used to evaluate categorical variables,
and the Student’s t-test and Wilcoxon test were used to evaluate
continuous variables. Statistical signiﬁcance was set at p < 0.05.
2.2. Characterization of probiotic use
The clinical information system was queried for any inpatient
prescribed any Saccharomyces-, Lactobacillus-, or Biﬁdobacter-
ium-based probiotic during the 1-year period from 2007 to 2008.
In order to characterize the inpatient probiotic prescribing
patterns, all patients already taking probiotics at the time of
admission were excluded. A retrospective chart review was
conducted to obtain information regarding: (1) type and duration
of probiotics prescribed; (2) type of prescribing provider; (3)
indications for probiotic prescription; and (4) patient character-
istics, including immunosuppression, impaired intestinal integrity,
and abnormal heart valves.
Immunosuppression was characterized as mild, moderate, or
severe. Mild immunosuppression was deﬁned as age 80 years, or
the presence of chronic renal disease, diabetes mellitus, cirrhosis,
or non-hematologic cancer. Moderate immunosuppression was
deﬁned as HIV-positive with a CD4 count >200/mm3, concurrentsystemic steroid administration, or two or more of the criteria for
mild immunosuppression. Severe immunosuppression was de-
ﬁned as the presence of either a solid organ transplant, AIDS (CD4
count <200/mm3), neutropenia (absolute neutrophil count <1000/
ml), or hematologic malignancy.
Impaired intestinal integrity was deﬁned in any patient with
abdominal imaging identifying either bowel thickening, dilatation,
or diverticulitis within 2 weeks of taking a probiotic; colonoscopy
identifying colitis within 2 weeks of taking a probiotic; or any
bowel surgery within 4 weeks of taking a probiotic.
Heart valve abnormality was deﬁned as a history of any heart
valve replacement or repair, or any echocardiogram indicating
moderate or severe valvular insufﬁciency or stenosis within 6
months prior to taking a probiotic.
2.3. Estimation of the incidence of probiotic-associated bloodstream
infection
The clinical information system was electronically queried for
any inpatient prescribed Lactobacillus-, Saccharomyces-, or
Biﬁdobacterium-based oral probiotics during the 8-year period
from 2000 to 2008. The list was then cross-referenced against a list
of any patient with blood cultures positive for any Lactobacillus,
Saccharomyces, or Biﬁdobacterium species to identify patients with
potential probiotic-related bloodstream infections. Infections were
only considered probiotic-related if the patient had been
prescribed probiotics in the previous 30 days and they exhibited
signs and symptoms of infection, including persistent fever.
Incidence rates were expressed as the number of potential
probiotic-related bloodstream infections/number of patients
prescribed that speciﬁc probiotic during the 8-year study period.
The calculation of incidence rates of infection was restricted to
only those probiotics with sufﬁciently large enough patient
prescription rates to allow robust estimates.
3. Results
3.1. Characterization of probiotic use
Four hundred inpatients were prescribed probiotics from 2007
to 2008, yielding a frequency of 0.4% (579 probiotic inpatient
courses/128 949 admissions). Three hundred eighty-ﬁve (96%)
received Lactobacillus acidophilus/Lactobacillus bulgaricus and 15
(4%) received S. boulardii; none received Biﬁdobacterium. Patients
on probiotics at the time of the admission (n = 18) and patients
with incomplete medical records (n = 22) were excluded. In
addition, patients receiving S. boulardii probiotics were also
excluded because there were only a few cases. Thus, 345 patients
receiving a single L. acidophilus/L. bulgaricus probiotic preparation
were included in the analysis. Fifty-nine percent were female and
41% were male (p < 0.001), and the mean patient age was
65.9  18 years. The median duration of inpatient probiotic
treatment was 5 days (range 1–15 days).
Probiotics were prescribed by 191 different health care
providers. Of these, 149 (78%) were physicians and 40 (21%) were
physician assistants or nurse practitioners; job title was unknown
for two (1%) prescribers. Probiotics were primarily prescribed by
the medicine service (n = 148; 77%), followed by surgery (n = 8;
4%), medical rehabilitation (n = 5; 3%), pediatrics (n = 5; 3%), family
medicine (n = 3; 2%), anesthesiology (n = 3; 2%), obstetrics/
gynecology (n = 2; 1%), critical care medicine (n = 2; 1%), and
others or unknown (n = 15; 8%).
The most common indications for probiotic use, which
accounted for 72% of all indications, were treatment of Clostridium
difﬁcile infection or unspeciﬁed diarrhea, and prevention of
antibiotic-associated diarrhea (see Table 1).
Table 1
Indications for probiotic use (N = 345)a
Indication n (%)
Clostridium difﬁcile treatment 103 (29.9)
Unspeciﬁed diarrhea treatment 91 (26.4)
Antibiotic-associated diarrhea prevention 55 (15.9)
Clostridium difﬁcile prevention 21 (6.1)
Unknown 57 (16.5)
Other indications 18 (5.2)
Yeast infection 2 (0.6)
Liver encephalopathy 4 (1.2)
Peptic ulcer disease 2 (0.6)
Irritable bowel syndrome 2 (0.6)
Patient’s request 1 (0.3)
Constipation 2 (0.6)
Cryptosporidium 1 (0.3)
Ischemic colitis 1 (0.3)
Unspeciﬁed colitis 3 (0.9)
a Each patient had only one probiotic indication.
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345 patients (47%) patients had either moderate or severe
immunosuppression: 124 (36%) were moderately immunosup-
pressed and 37 (11%) were severely immunosuppressed (see Table
2). One hundred fourteen of 345 patients (33%) had impaired
intestinal integrity: 104 (30%) by abnormal abdominal imaging
studies, 16 (5%) by abnormal colonoscopy, and eight (2%) by recent
history of bowel surgery. Imaging studies and colonoscopies were
done on 175 (51%) and 27 (8%) of the patients, respectively. Sixty-
eight of 345 patients (20%) had abnormal heart valves: 62 (18%)
identiﬁed as having moderate and/or severe heart valve abnor-
malities on echocardiogram and 14 (4%) as having a history of
cardiac valve replacement or repair. Tricuspid regurgitation was
the most common moderate heart valve abnormality seen (29
cases), followed by mitral regurgitation with 17 cases. For severe
abnormalities, mitral regurgitation was the most common (eight
cases), followed by tricuspid regurgitation (ﬁve cases). An
echocardiogram was performed in 213 (62%) of the patients.
Mitral valve replacement was the most common surgery
performed (six cases), followed by aortic valve replacement (ﬁve),
mitral valve repair (three), tricuspid valve repair (one), and
tricuspid valve replacement (one).
3.2. Estimation of the incidence of probiotic-associated bloodstream
infection
Two of 1176 (0.2%) patients developed what could be
considered a potential probiotic-related bloodstream infection
during the 8-year period (2000–2008).
The ﬁrst case was a 66-year-old female with history of diabetes
mellitus and end-stage renal disease, who was receiving aTable 2
Immunosuppressive conditions (N = 345)a
Condition n (%)
Elderly (80 years) 94 (27.2)
Chronic kidney disease 68 (19.7)
Diabetes mellitus 135 (39.1)
Cirrhosis 17 (4.9)
HIV 21 (6.1)
CD4+ <200/mm3 16 (4.6)
CD4+ >200/mm3 5 (1.4)
Systemic steroids 31 (9.0)
Non-hematologic cancer 54 (15.7)
Solid transplant patients 8 (2.3)
Neutropenia (<1000/ml) 14 (4.1)
Hematologic malignancies 10 (2.9)
a Some patients had more than one immunosuppressive condition.probiotic containing L. acidophilus/L. bulgaricus for a recent C.
difﬁcile infection and who presented with fever and a right lower
extremity cellulitis. Admission blood cultures grew L. acidophilus
and group G Streptococcus. She was treated with ceftriaxone and
vancomycin for her cellulitis and her condition improved.
The second case was a 73-year-old female with a history of
diabetes mellitus, cholangiocarcinoma (status post chemothera-
py), and hepaticojejunostomy. She presented with a 2-day history
of fever, nausea, vomiting, and abdominal pain. Blood cultures
grew Lactobacillus. Computed tomography showed an abdominal
collection which was drained by interventional radiology;
Klebsiella pneumoniae grew on culture. She was treated with
piperacillin–tazobactam and improved. Just before she was
admitted she had completed a course of metronidazole and L.
acidophilus/L. bulgaricus for an unspeciﬁed diarrheal illness.
Given that this was a retrospective study and patient isolates
were no longer available, molecular typing of the patient
Lactobacillus isolates and the administered probiotic strains of
Lactobacillus could not be accomplished.
4. Discussion
In general, the inpatient prescription of probiotics at our
academic tertiary care facility, where probiotics have a non-
formulary status, was infrequent. Nonetheless, we were able to
identify 400 inpatients who were prescribed probiotics over a 1-
year period.
Data indicate that when probiotics were prescribed, Lactoba-
cillus-based products were chosen 96% of the time. Physicians
wrote 78% of these prescriptions, primarily connected to the
medical service, and did so mainly for the treatment of C. difﬁcile
infection or unspeciﬁed diarrhea and for the prevention of
antibiotic-associated diarrhea (combined, 72% of indications).
While there are data supporting the use of probiotics for C. difﬁcile
infection,2 the Infectious Diseases Society of America, in conjunc-
tion with the Society for Healthcare Epidemiology of America, has
stated that ‘‘Administration of currently available probiotics is not
recommended to prevent primary Clostridium difﬁcile infection, as
there are limited data to support this approach and there is a
potential risk of bloodstream infection.’’27
Overall, we were surprised to discover the frequency with
which probiotics were given to patients who might be considered
traditionally at high risk for probiotic-associated bloodstream
infection. Forty-seven percent of the patients were either
moderately or severely immunosuppressed. One third had
impaired intestinal integrity and one ﬁfth had abnormal heart
valves. Sixty-nine percent had at least one risk factor and 24% had
at least two risk factors for probiotic-associated infection.
The risk of probiotic-related bloodstream infection associated
with the inpatient prescription of a L. acidophilus/L. bulgaricus
probiotic was quite low at our institution (maximal estimate of
0.2%). Only two cases of potential probiotic-related infection were
identiﬁed, the ﬁrst patient was considered moderately immuno-
suppressed and the second patient had impaired intestinal
integrity based on our criteria. Interestingly, both improved after
broad-spectrum antibiotic therapy for unrelated concurrent
infections (which also provided Lactobacillus coverage). Unfortu-
nately, the two cases were not conﬁrmed by typing. Therefore, we
could not conclusively link probiotic intake with bloodstream
infection, since these organisms can also routinely reside in the
intestinal ﬂora.28,29
Among the limitations of our study, it is important to mention
that the criteria used for the degree of immunosuppression were
somewhat arbitrary, so it is possible that immunosuppression
could have been overestimated in some patients. In addition, only
10% of our patient sample had severe immunosuppression and the
J. Simkins et al. / International Journal of Infectious Diseases 17 (2013) e321–e324e324risk of infection may have been underestimated in this patient
category.
In conclusion, we found that the use of probiotics containing L.
acidophilus/L. bulgaricus at our institution was relatively safe, even
though they were frequently prescribed to inpatients who could be
considered at high risk for probiotic-related bloodstream infection.
However trivial the estimated risk of bloodstream infection
associated with L. acidophilus/L. bulgaricus-based probiotic use
appears, it needs to be part of a cost–beneﬁt analysis that includes
some evidence of clinical efﬁcacy for the condition it is being
prescribed for. Thus, until this type of information becomes
available and the data are evaluated, it would seem prudent to
continue not to recommend the widespread use of this probiotic
based on its safety proﬁle alone.
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